1. FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. (12th June 2018) Authors: Alten, R.; Tseluyko, V.; Hala, T.; Mehmedagic, S.; Pileckyte, M.; Dokoupilová, E.; Jovic, D.; Rehman, M.; Zhang, M.; Sewell, L.; Hackley, S.; Salts, S.; Cronenberger, C.; Schumacher, K.; von Richter, O.; Batko, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LB0004 Efficacy and safety of nnc0109-0012 (anti-IL-20 MAB) in patients with rheumatoid arthritis: Results from a phase 2a trial. (23rd January 2014) Authors: Šenolt, L.; Göthberg, M.; Valencia, X.; Dokoupilová, E. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0433 Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial. (9th June 2015) Authors: Rahman, P.; Strand, V.; McInnes, I.B.; Marzo-Ortega, H.; Dokoupilová, E.; Churchill, M.; Kandala, S.; Pricop, L.; Mpofu, S. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 356 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗